Stay updated on 12-Week Psoriasis Dose-Ranging Clinical Trial
Sign up to get notified when there's something new on the 12-Week Psoriasis Dose-Ranging Clinical Trial page.

Latest updates to the 12-Week Psoriasis Dose-Ranging Clinical Trial page
- Check6 days agoChange DetectedThe ClinicalTrials.gov record for a 12-week dose-ranging trial of IMO-8400 in people with moderate to severe plaque psoriasis is displayed instead of an error page. It provides the study’s participation criteria, treatment plan, and primary safety outcome.SummaryDifference45%

- Check13 days agoChange DetectedThe ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check20 days agoChange DetectedA site-wide NIH banner announces a transition from the term “Artificial Intelligence” to “Super Intelligence.” It appears above the unavailable study record and does not add study-specific details.SummaryDifference1%

- Check27 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe site footer’s revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 error, replacing the study record content with an access-denied screen, effectively making the study details unavailable at this time.SummaryDifference18%

Stay in the know with updates to 12-Week Psoriasis Dose-Ranging Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 12-Week Psoriasis Dose-Ranging Clinical Trial page.